Developer docs
API playgroundTry for free, no card

Search company profiles

Interpharma Praha

Full company profile

uuid002oj4a

Namestring
Interpharma Praha
Legal namestring
Interpharma Praha, a.s.
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Interpharma Praha, a.s. (also known as IPP) was a Czech contract development and manufacturing organization (CDMO) that provided research, development, and manufacturing services in the fields of pharmaceutical active substances (léčivé substance) and nutraceuticals / food supplements (doplňky stravy). Legally registered as a joint-stock company (akciová společnost, or a.s.) on 31 December 1991, the firm was headquartered at Komořanská 955/61, Prague 4 – Modřany, Czech Republic, and operated as part of the wider Otsuka pharmaceutical network, with documented affiliation to Otsuka Novel Products and to OTSUKA Pharmaceutical Development and Commercialization, Inc. in Princeton, New Jersey. Day-to-day executive leadership rested with CEO Shin Ogasawara, COO and Board Member Ing. Ivan Hlaváček, CSc., and Head of Business Department Natalia Ziňkova, with PRK Partners providing external legal counsel.

The firm's core offering was pharmaceutical and nutraceutical development and manufacturing, but the source data does not disclose named product brands, specific formulations, a distinct technology platform, or proprietary process IP; the technical footprint is best characterized as conventional small-scale pharmaceutical and food supplement CDMO activity tied to the Otsuka group's pipeline. There is no app, API, AI/ML capability, integration, or notable digital product surface disclosed, and the company's own website search returns no matches for indexed product pages.

Commercially, Interpharma Praha functioned in a B2B, intra-group CDMO capacity with no publicly disclosed revenue, pricing model, customer list, or marketing or distribution channel activity. The company extended its geographic reach only within Central Europe (the Czech Republic), with all commercial coordination routed through the Otsuka parent and affiliate network. Citing changes in the business environment, Interpharma Praha terminated all business operations on March 31, 2026 and initiated the legal procedures required for liquidation.

Short descriptiontext

Interpharma Praha, a.s. was a Czech pharmaceutical and nutraceutical contract development and manufacturing organization (CDMO) operating within the Otsuka group, providing R&D and manufacturing services for drug substances and food supplements before ceasing operations on March 31, 2026.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrague, Czechia
HQ citystring
Prague
HQ countrystring
Czechia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, nutraceutical product development, drug substance manufacturing, contract research organization, dietary supplement manufacturing
Industry2 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing (CDMO)
No data
Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Interpharma Praha, a.s. was a Contract Development and Manufacturing Organization (CDMO) that provided research, development, and manufacturing services for pharmaceutical substances and nutraceutical/dietary supplement products. The company operated within the Otsuka pharmaceutical group, serving affiliated entities from its facility in Prague 4 – Modřany, Czech Republic. All business operations ceased on March 31, 2026 and the company entered liquidation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Interpharma Praha, a.s. (IPP) was a Contract Development and Manufacturing Organization (CDMO) providing research, development, and manufacturing services in the fields of pharmaceuticals (léčivé substance) and nutraceuticals (doplňky stravy). The company operated as part of the Otsuka group, specifically aligned with Otsuka Novel Products and OTSUKA Pharmaceutical Development and Commercialization, Inc. Based in Prague 4 – Modřany, the company ceased all business operations on March 31, 2026, and initiated legal proceedings for liquidation. No specific named product brands, individual formulations, or distinct service modules were identified in the available source material.

Product and service2 records
1Pharmaceutical R&D and Contract Manufacturing Services
CategoryPharmaceutical CDMO services
Description

Contract research, development, and manufacturing services for pharmaceutical drug substances, delivered to affiliated Otsuka group entities (Otsuka Novel Products; OTSUKA Pharmaceutical Development and Commercialization, Inc.) from the Prague 4 – Modřany facility.

2Nutraceutical (Food Supplement) R&D and Contract Manufacturing Services
CategoryNutraceutical CDMO services
Description

Contract research, development, and manufacturing services for food supplements and nutraceutical products, delivered to affiliated Otsuka entities and channeled through the IPP Business Department.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent/affiliate company within the Otsuka group. Interpharma Praha operated as part of the Otsuka pharmaceutical network, providing manufacturing services for the group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

U.S.-based affiliate located at 508 Carnegie Center Drive, Princeton, New Jersey 08540. Part of the Otsuka group that Interpharma Praha served, with coordination on pharmaceutical development and commercialization activities.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

European CDMO offering pharmaceutical and nutraceutical manufacturing services across multiple dosage forms, directly comparable to Interpharma Praha's combination of regulated and consumer health CDMO work.

TypeBroad incumbent
Description

Global CDMO leader with extensive small-molecule API and drug product capabilities, comparable as a broad incumbent in the same CDMO market in which Interpharma Praha operated.

TypeDirect peer
Description

German API manufacturer and CDMO serving global pharmaceutical companies, comparable in its focus on small-molecule active ingredients and European regulatory expertise.

TypeEmerging player
Description

European contract development and manufacturing services arm of Eurofins, serving pharmaceutical and nutraceutical clients with overlapping CDMO capabilities relevant to a small European drug-substance manufacturer.

5Recipharm
TypeDirect peer
Description

Sweden-headquartered European CDMO providing contract development and manufacturing of pharmaceuticals, comparable in scope of small-molecule drug substance and drug product services.

TypeBroad incumbent
Description

Global large-scale CDMO providing development and manufacturing services across small and large molecules; broader in scope and scale than Interpharma Praha but operates in the same overall CDMO category.

TypeDirect peer
Description

Portugal-based CDMO specializing in small-molecule API development and manufacturing for global pharma, the most direct functional and geographic comparable to Interpharma Praha's drug-substance CDMO model.

TypeDirect peer
Description

France-based integrated API and intermediates CDMO, closely aligned with Interpharma Praha's focus on small-molecule active substance manufacturing for global pharma clients.

TypeDirect peer
Description

US-based CDMO offering small-molecule API development and drug product manufacturing services, comparable in service portfolio to a niche pharma CDMO of Interpharma Praha's scale.

TypeDirect peer
Description

European CDMO combining prescription pharma development and manufacturing with nutraceutical/dietary supplement capabilities, mirroring Interpharma Praha's dual pharma + nutraceutical service mix.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Interpharma Praha

Pharmaceutical Contract Manufacturing (CDMO)interpharma-praha.com

Interpharma Praha, a.s. was a Czech pharmaceutical and nutraceutical contract development and manufacturing organization (CDMO) operating within the Otsuka group, providing R&D and manufacturing services for drug substances and food supplements before ceasing operations on March 31, 2026.

What Interpharma Praha does

Interpharma Praha, a.s. (also known as IPP) was a Czech contract development and manufacturing organization (CDMO) that provided research, development, and manufacturing services in the fields of pharmaceutical active substances (léčivé substance) and nutraceuticals / food supplements (doplňky stravy). Legally registered as a joint-stock company (akciová společnost, or a.s.) on 31 December 1991, the firm was headquartered at Komořanská 955/61, Prague 4 – Modřany, Czech Republic, and operated as part of the wider Otsuka pharmaceutical network, with documented affiliation to Otsuka Novel Products and to OTSUKA Pharmaceutical Development and Commercialization, Inc. in Princeton, New Jersey. Day-to-day executive leadership rested with CEO Shin Ogasawara, COO and Board Member Ing. Ivan Hlaváček, CSc., and Head of Business Department Natalia Ziňkova, with PRK Partners providing external legal counsel.

The firm's core offering was pharmaceutical and nutraceutical development and manufacturing, but the source data does not disclose named product brands, specific formulations, a distinct technology platform, or proprietary process IP; the technical footprint is best characterized as conventional small-scale pharmaceutical and food supplement CDMO activity tied to the Otsuka group's pipeline. There is no app, API, AI/ML capability, integration, or notable digital product surface disclosed, and the company's own website search returns no matches for indexed product pages.

Commercially, Interpharma Praha functioned in a B2B, intra-group CDMO capacity with no publicly disclosed revenue, pricing model, customer list, or marketing or distribution channel activity. The company extended its geographic reach only within Central Europe (the Czech Republic), with all commercial coordination routed through the Otsuka parent and affiliate network. Citing changes in the business environment, Interpharma Praha terminated all business operations on March 31, 2026 and initiated the legal procedures required for liquidation.

Interpharma Praha firmographics

Firmographics
Name
Interpharma Praha
Legal name
Interpharma Praha, a.s.
Website
https://interpharma-praha.com
Company type
Private
Founded year
1991
Operating status
Closed
Headcount range
11–50 employees
Short description
Interpharma Praha, a.s. was a Czech pharmaceutical and nutraceutical contract development and manufacturing organization (CDMO) operating within the Otsuka group, providing R&D and manufacturing services for drug substances and food supplements before ceasing operations on March 31, 2026.
Ownership category
akta.pro rank

Interpharma Praha industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical contract manufacturing
  • Nutraceutical product development
  • Drug substance manufacturing
  • Contract research organization
  • Dietary supplement manufacturing

Where Interpharma Praha is headquartered

Location

Headquarters

HQ city
Prague
HQ country
Czechia
HQ region
Europe

Offices1 record

Markets served

Interpharma Praha business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Interpharma Praha product offering

Product offering

Core offering

Interpharma Praha, a.s. was a Contract Development and Manufacturing Organization (CDMO) that provided research, development, and manufacturing services for pharmaceutical substances and nutraceutical/dietary supplement products. The company operated within the Otsuka pharmaceutical group, serving affiliated entities from its facility in Prague 4 – Modřany, Czech Republic. All business operations ceased on March 31, 2026 and the company entered liquidation.

Product overview

Interpharma Praha, a.s. (IPP) was a Contract Development and Manufacturing Organization (CDMO) providing research, development, and manufacturing services in the fields of pharmaceuticals (léčivé substance) and nutraceuticals (doplňky stravy). The company operated as part of the Otsuka group, specifically aligned with Otsuka Novel Products and OTSUKA Pharmaceutical Development and Commercialization, Inc. Based in Prague 4 – Modřany, the company ceased all business operations on March 31, 2026, and initiated legal proceedings for liquidation. No specific named product brands, individual formulations, or distinct service modules were identified in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical R&D and Contract Manufacturing Services Contract research, development, and manufacturing services for pharmaceutical drug substances, delivered to affiliated Otsuka group entities (Otsuka Novel Products; OTSUKA Pharmaceutical Development and Commercialization, Inc.) from the Prague 4 – Modřany facility.
  • Nutraceutical (Food Supplement) R&D and Contract Manufacturing Services Contract research, development, and manufacturing services for food supplements and nutraceutical products, delivered to affiliated Otsuka entities and channeled through the IPP Business Department.

Companies that use Interpharma Praha

Customer profile

Segments1 record

Ideal customer profiles1 record

Interpharma Praha technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Interpharma Praha partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Otsuka Novel ProductscoreStrategic or Co-development PartnerParent/affiliate company within the Otsuka group. Interpharma Praha operated as part of the Otsuka pharmaceutical network, providing manufacturing services for the group.
  • OTSUKA Pharmaceutical Development and Commercialization, Inc.coreStrategic or Co-development PartnerU.S.-based affiliate located at 508 Carnegie Center Drive, Princeton, New Jersey 08540. Part of the Otsuka group that Interpharma Praha served, with coordination on pharmaceutical development and commercialization activities.

Scale indicators1 record

Recent moves4 records

Interpharma Praha competitors and assessment

Company assessment

Direct peers

  • NextPharma: European CDMO offering pharmaceutical and nutraceutical manufacturing services across multiple dosage forms, directly comparable to Interpharma Praha's combination of regulated and consumer health CDMO work.
  • PharmaZell: German API manufacturer and CDMO serving global pharmaceutical companies, comparable in its focus on small-molecule active ingredients and European regulatory expertise.
  • Recipharm: Sweden-headquartered European CDMO providing contract development and manufacturing of pharmaceuticals, comparable in scope of small-molecule drug substance and drug product services.
  • Hovione: Portugal-based CDMO specializing in small-molecule API development and manufacturing for global pharma, the most direct functional and geographic comparable to Interpharma Praha's drug-substance CDMO model.
  • SEQENS: France-based integrated API and intermediates CDMO, closely aligned with Interpharma Praha's focus on small-molecule active substance manufacturing for global pharma clients.
  • Alcami: US-based CDMO offering small-molecule API development and drug product manufacturing services, comparable in service portfolio to a niche pharma CDMO of Interpharma Praha's scale.
  • Aenova Group: European CDMO combining prescription pharma development and manufacturing with nutraceutical/dietary supplement capabilities, mirroring Interpharma Praha's dual pharma + nutraceutical service mix.

Broad incumbents

  • Lonza: Global CDMO leader with extensive small-molecule API and drug product capabilities, comparable as a broad incumbent in the same CDMO market in which Interpharma Praha operated.
  • Catalent: Global large-scale CDMO providing development and manufacturing services across small and large molecules; broader in scope and scale than Interpharma Praha but operates in the same overall CDMO category.

Emerging players

  • Eurofins CDMO: European contract development and manufacturing services arm of Eurofins, serving pharmaceutical and nutraceutical clients with overlapping CDMO capabilities relevant to a small European drug-substance manufacturer.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Interpharma Praha compliance and trust

Trust signal

Compliance1 record

Interpharma Praha financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Interpharma Praha leadership team

Management profile

Number of profiles

Profiles4 records

Interpharma Praha funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Interpharma Praha M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interpharma Praha

What does Interpharma Praha do?

Interpharma Praha, a.s. was a Contract Development and Manufacturing Organization (CDMO) that provided research, development, and manufacturing services for pharmaceutical substances and nutraceutical/dietary supplement products. The company operated within the Otsuka pharmaceutical group, serving affiliated entities from its facility in Prague 4 – Modřany, Czech Republic. All business operations ceased on March 31, 2026 and the company entered liquidation.

Is Interpharma Praha a public or private company?

Interpharma Praha is a private company. It is classified as corporate owned and is currently closed.

When was Interpharma Praha founded?

Interpharma Praha was founded in 1991. It employs 11 to 50 people.

Where is Interpharma Praha based?

Interpharma Praha is headquartered in Prague, Czechia, in the Europe region.

Who are Interpharma Praha's main competitors?

Direct peers on record are NextPharma, PharmaZell, Recipharm, Hovione, SEQENS, Alcami and Aenova Group. Broad incumbents are Lonza and Catalent. Eurofins CDMO is listed as an emerging player.

Does Interpharma Praha have an API?

No public API is recorded for Interpharma Praha.

What industry is Interpharma Praha in?

Interpharma Praha's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales